Literature DB >> 17622486

Safety and efficacy of fractionated stereotactic radiotherapy for acoustic neuromas.

Shearwood McClelland1, Bruce J Gerbi, Patrick D Higgins, James B Orner, Walter A Hall.   

Abstract

BACKGROUND: The treatment of acoustic neuromas (AN) has historically involved surgical excision or stereotactic radiosurgery, with a relatively limited number of reports available describing the use of fractionated stereotactic radiotherapy (FSRT). To enhance the existing knowledge regarding the safety and efficacy of this treatment modality, we describe our initial experience with FSRT for AN.
METHODS: From 1999-2005, 20 patients (12F, 8M) with AN underwent FSRT. All patients were treated using the Radionics X-Knife 4.0 3D planning system, receiving 54 Gy in 1.8 Gy daily fractions with a prescription isodose line of 90%. Treatments were delivered stereotactically using a dedicated Varian 6/100 linear accelerator, with immobilization achieved via the Gill-Thomas-Cosman relocatable frame. Median tumor size (maximum diameter) was 2.1 cm (range, 1.1-3.4 cm). Median patient age was 49.5 years, with median follow-up of 22 months (range, 1-66 months). All patients were evaluated with pre- and post-gadolinium-enhanced magnetic resonance imaging.
RESULTS: Following FSRT, local tumor control was achieved in every patient, with the treatment well-tolerated by all patients. No patient experienced acute complications or facial nerve weakness. Two patients experienced permanent trigeminal nerve morbidity manifesting as facial numbness. All nine patients with preserved hearing before treatment had hearing preservation at last follow-up, although four of these patients experienced hearing decline following FSRT.
CONCLUSION: In our series of 20 patients with AN, all had local tumor control following FSRT, with minimal morbidity. These results support the growing body of literature demonstrating the safety and efficacy of FSRT in achieving local control for AN, further validating the viability of FSRT as a treatment modality for this patient population.

Entities:  

Mesh:

Year:  2007        PMID: 17622486     DOI: 10.1007/s11060-007-9456-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  34 in total

1.  Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy.

Authors:  Rahul Chopra; Douglas Kondziolka; Ajay Niranjan; L Dade Lunsford; John C Flickinger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-26       Impact factor: 7.038

2.  Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years.

Authors:  Toshinori Hasegawa; Shigeru Fujitani; Shun Katsumata; Yoshihisa Kida; Masayuki Yoshimoto; Joji Koike
Journal:  Neurosurgery       Date:  2005-08       Impact factor: 4.654

3.  Radiosurgery of vestibular schwannomas: summary of experience in 829 cases.

Authors:  L Dade Lunsford; Ajay Niranjan; John C Flickinger; Ann Maitz; Douglas Kondziolka
Journal:  J Neurosurg       Date:  2005-01       Impact factor: 5.115

4.  Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution.

Authors:  D W Andrews; O Suarez; H W Goldman; M B Downes; G Bednarz; B W Corn; M Werner-Wasik; J Rosenstock; W J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-08-01       Impact factor: 7.038

5.  Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity.

Authors:  Annie W Chan; Peter Black; Robert G Ojemann; Fred G Barker; Hanne M Kooy; Vrishali V Lopes; Michael J McKenna; Dennis C Shrieve; Robert L Martuza; Jay S Loeffler
Journal:  Neurosurgery       Date:  2005-07       Impact factor: 4.654

6.  Linear accelerator radiosurgery for vestibular schwannomas.

Authors:  William A Friedman; Patrick Bradshaw; Adam Myers; Frank J Bova
Journal:  J Neurosurg       Date:  2006-11       Impact factor: 5.115

7.  Preservation of cranial nerve function after treatment of acoustic neurinomas with fractionated stereotactic radiotherapy. Preliminary observations in 26 patients.

Authors:  D W Andrews; C L Silverman; J Glass; B Downes; R J Riley; B W Corn; M Werner-Wasik; W J Curran; C E McCune; R H Rosenwasser
Journal:  Stereotact Funct Neurosurg       Date:  1995       Impact factor: 1.875

8.  Intracanalicular acoustic neuroma: early surgery for preservation of hearing.

Authors:  S J Haines; S C Levine
Journal:  J Neurosurg       Date:  1993-10       Impact factor: 5.115

9.  Fractionated stereotactic radiotherapy for pituitary adenomas following microsurgical resection: safety and efficacy.

Authors:  Shearwood McClelland; Patrick D Higgins; Bruce J Gerbi; James B Orner; Walter A Hall
Journal:  Technol Cancer Res Treat       Date:  2007-06

10.  The preservation of hearing and facial nerve function in a consecutive series of unilateral vestibular nerve schwannoma surgical patients (acoustic neuroma).

Authors:  L J Cerullo; J F Grutsch; K Heiferman; R Osterdock
Journal:  Surg Neurol       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.